New NPY2R Activator BI 1820237 Boosts Weight Loss When Combined with Survodutide Targeting Glucagon and GLP-1 Receptors

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: This work was supported by Boehringer Ingelheim Pharma GmbH & Co KG. Robert Augustin reports a relationship with Boehringer Ingelheim Pharma GmbH & Co KG that includes: employment. Anouk Oldenburger reports a relationship with Boehringer Ingelheim Pharma GmbH & Co KG that includes: employment. Tamara Baader-Pagler reports a relationship with Boehringer Ingelheim Pharma GmbH & Co KG that includes: employment. Tina Zimmermann reports a relationship with Boehringer Ingelheim Pharma GmbH & Co KG that includes: employment. Jens Borghardt reports a relationship with Boehringer Ingelheim Pharma GmbH & Co KG that includes: employment. Jacob Hecksher-Sørensen reports a relationship with Gubra A/S that includes: employment. Angela Baljuls reports a relationship with Boehringer Ingelheim Pharma GmbH & Co KG that includes: employment. Wolfgang Reindl reports a relationship with Boehringer Ingelheim Pharma GmbH & Co KG that includes: employment. Bartlomiej Krawczyk reports a relationship with Boehringer Ingelheim Pharma GmbH & Co KG that includes: employment. Eric Martel reports a relationship with Boehringer Ingelheim Pharma GmbH & Co KG that includes: employment. Albert Brennauer reports a relationship with Boehringer Ingelheim Pharma GmbH & Co KG that includes: employment. Stefan Peters reports a relationship with Boehringer Ingelheim Pharma GmbH & Co KG that includes: employment. Achim Grube reports a relationship with Boehringer Ingelheim Pharma GmbH & Co KG that includes: employment. Lise Biehl Rudkjaer reports a relationship with Gubra A/S that includes: employment. Peter Haebel reports a relationship with Boehringer Ingelheim Pharma GmbH & Co KG that includes: employment. RA, PH, TBP, TZ, BK, JB, EM, ABa, ABr, AG, WR are employees of Boehringer Ingelheim. AO is an employee of Novo Nordisk A/S; at the time of project initiation, AO was an employee of Boehringer Ingelheim. JHS, LBR are employees of Gubra A/S. RA, AO, ABr, SP, and PH are listed as inventors on patent(s) related to this work (owned by Boehringer Ingelheim International GmbH); they do not receive any direct financial compensation related to the patent(s). If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.